CEL-SCI Corp Market Cap ($12.01 Million)
Market Cap & Net Worth: CEL-SCI Corp (CVM)
CEL-SCI Corp market cap. CEL-SCI Corp (NYSE MKT:CVM) has a market capitalization of $12.01 Million ($12.01 Million) as of November 1, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #26474 globally and #5535 in its home market, demonstrating a 9.23% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CEL-SCI Corp's stock price $1.42 by its total outstanding shares 8457967 (8.46 Million). Also see CEL-SCI Corp cash flow conversion for how efficiently the company converts equity into cash flow.
CEL-SCI Corp Market Cap History (2015–2026)
CEL-SCI Corp market cap history from 2015 to 2026. Data shows change from $78.24 Million to $12.01 Million (-21.51% CAGR). Check latest CEL-SCI Corp stock price today for real-time trading data and today's change.
CEL-SCI Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CEL-SCI Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore CVM net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
176.53x
CEL-SCI Corp's market cap is 176.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $14.21 Million | $285.06K | -$11.47 Million | 49.85x | N/A |
| 2017 | $15.98 Million | $69.02K | -$14.36 Million | 231.58x | N/A |
| 2018 | $24.27 Million | $476.56K | -$31.84 Million | 50.94x | N/A |
| 2019 | $77.39 Million | $462.75K | -$24.69 Million | 167.24x | N/A |
| 2020 | $98.62 Million | $558.66K | -$32.22 Million | 176.53x | N/A |
Competitor Companies of CVM by Market Capitalization
Companies near CEL-SCI Corp in the global market cap rankings as of November 1, 2026. Also see CEL-SCI Corp asset portfolio for a full breakdown of the balance sheet.
Key companies related to CEL-SCI Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of CEL-SCI Corp (2015–2026)
Market capitalization of CEL-SCI Corp from 2015 to today. Between 2015 and today, CEL-SCI Corp's market cap moved from $78.24 Million to $ 12.01 Million, with a yearly change of -21.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $12.01 Million | -73.00% |
| 2025 | $44.49 Million | +1215.33% |
| 2024 | $3.38 Million | -85.30% |
| 2023 | $23.01 Million | +15.74% |
| 2022 | $19.88 Million | -66.90% |
| 2021 | $60.05 Million | -39.11% |
| 2020 | $98.62 Million | +27.43% |
| 2019 | $77.39 Million | +218.82% |
| 2018 | $24.27 Million | +51.87% |
| 2017 | $15.98 Million | +12.49% |
| 2016 | $14.21 Million | -81.84% |
| 2015 | $78.24 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of CEL-SCI Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.01 Million USD |
| MoneyControl | $12.01 Million USD |
| MarketWatch | $12.01 Million USD |
| marketcap.company | $12.01 Million USD |
| Reuters | $12.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CEL-SCI Corp
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation S… Read more